0000000000025970

AUTHOR

Luc Mouthon

showing 7 related works from this author

Reducing the initial number of rituximab maintenance-therapy infusions for ANCA-associated vasculitides: randomized-trial post-hoc analysis

2020

AbstractObjectiveThe randomized, controlled MAINRITSAN2 trial was designed to compare the capacity of an individually tailored therapy [randomization day 0 (D0)], with reinfusion only when CD19+ lymphocytes or ANCA had reappeared, or if the latter’s titre rose markedly, with that of five fixed-schedule 500-mg rituximab infusions [D0 + D14, then months (M) 6, 12 and 18] to maintain ANCA-associated vasculitis (AAV) remissions. Relapse rates did not differ at M28. This ancillary study was undertaken to evaluate the effect of omitting the D14 rituximab infusion on AAV relapse rates at M12.MethodsMAINRITSAN2 trial data were subjected to post-hoc analyses of M3, M6, M9 and M12 relapse-free surviv…

medicine.medical_specialtyRandomizationAntigens CD19Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisGastroenterologyDisease-Free SurvivalDrug Administration ScheduleAntibodies Antineutrophil CytoplasmicMaintenance Chemotherapylaw.invention03 medical and health sciences0302 clinical medicineRheumatologyMaintenance therapyRandomized controlled triallawInternal medicinePost-hoc analysismedicineHumansPharmacology (medical)030212 general & internal medicineSurvival rate030203 arthritis & rheumatologybusiness.industrymedicine.diseaseAntirheumatic AgentsRituximabRituximabMicroscopic polyangiitisGranulomatosis with polyangiitisbusinessmedicine.drugRheumatology
researchProduct

Management of giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA).

2016

Abstract Purpose Management of giant cell arteritis (GCA, Horton's disease) involves many uncertainties. This work was undertaken to establish French recommendations for GCA management. Methods Recommendations were developed by a multidisciplinary panel of 33 physicians, members of the French Study Group for Large Vessel Vasculitis (Groupe d’etude francais des arterites des gros vaisseaux [GEFA]). The topics to be addressed, selected from proposals by group members, were assigned to subgroups to summarize the available literature and draft recommendations. Following an iterative consensus-seeking process that yielded consensus recommendations, the degree of agreement among panel members was…

medicine.medical_specialtyConsensusConsensus Development Conferences as TopicGiant Cell ArteritisDiseaseRecommendations03 medical and health sciences0302 clinical medicineLarge vessel vasculitisDiagnosismedicineInternal MedicineHumans030212 general & internal medicineIntensive care medicineExpert TestimonySocieties Medical030203 arthritis & rheumatologyModalitiesbusiness.industryBiologic therapiesGastroenterologyTemporal artery biopsymedicine.diseaseSurgeryTreatmentGiant cell arteritisRegimenAdjunctive treatmentCommittee MembershipFrancebusinessAlgorithmsLa Revue de medecine interne
researchProduct

Risk of scleroderma according to the type of immune checkpoint inhibitors

2020

Abstract Introduction Immune checkpoint inhibitors (ICIs) are associated with immune-related adverse events (irAEs). Among them, ICIs-induced systemic sclerosis (SSc) is poorly known. Methods To better characterize this irAE, our comprehensive approach combined the description of ICIs-induced scleroderma cases, the systematic review of the literature and the analysis of VigiBase, the WHO pharmacovigilance database. Results We identified two cases with underlying limited cutaneous SSc who presented a dramatic increase in the skin thickening following pembrolizumab, associated with scleroderma renal crisis in one case. In the literature, four cases of scleroderma and four cases of morphea hav…

Riskmedicine.medical_specialtyScleroderma SystemicDurvalumabintegumentary systembusiness.industryImmunologyScleroderma Renal CrisisIpilimumabPembrolizumabmedicine.diseaseDermatologySclerodermaAntineoplastic Agents ImmunologicalAtezolizumabNeoplasmsmedicineHumansImmunology and AllergyNivolumabskin and connective tissue diseasesbusinessMorpheamedicine.drugAutoimmunity Reviews
researchProduct

Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis.

2012

International audience; OBJECTIVE: Giant cell arteritis (GCA) is the most frequently occurring vasculitis in elderly individuals, and its pathogenesis is not fully understood. The objective of this study was to decipher the role of the major CD4+ T cell subsets in GCA and its rheumatologic form, polymyalgia rheumatica (PMR). METHODS: A prospective study of the phenotype and the function of major CD4+ T cell subsets (Th1, Th17, and Treg cells) was performed in 34 untreated patients with GCA or PMR, in comparison with 31 healthy control subjects and with the 27 treated patients who remained after the 7 others withdrew. RESULTS: Compared with control subjects, patients with GCA and patients wi…

MalePathologyMESH: Th17 CellsCellMESH : AgedMESH : Prospective StudiesMESH: Flow CytometryT-Lymphocytes RegulatoryPathogenesisMESH : T-Lymphocytes Regulatory0302 clinical medicineimmune system diseasesMESH : Th1 CellsImmunology and Allergy[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyPharmacology (medical)MESH : FemaleProspective Studiesskin and connective tissue diseasesCells CulturedMESH: Aged0303 health sciencesMESH: Middle Agedmedicine.diagnostic_testMESH: Giant Cell ArteritisCell DifferentiationMESH : AdultMiddle AgedFlow CytometryMESH : NK Cell Lectin-Like Receptor Subfamily B3. Good healthMESH: NK Cell Lectin-Like Receptor Subfamily Bmedicine.anatomical_structure[SDV.IMM]Life Sciences [q-bio]/ImmunologyFemaleVasculitisMESH : Cell DifferentiationGlucocorticoidmedicine.drugNK Cell Lectin-Like Receptor Subfamily BMESH: Cells CulturedAdultMESH: Cell Differentiationmedicine.medical_specialty[SDV.IMM] Life Sciences [q-bio]/ImmunologyMESH : Flow CytometryT cellMESH : MaleImmunologyGiant Cell ArteritisBiologyPolymyalgia rheumatica03 medical and health sciencesRheumatologyBiopsyMESH : Cells CulturedmedicineMESH : Th17 CellsHumansMESH : Middle Aged030304 developmental biologyAged030203 arthritis & rheumatologyMESH: HumansMESH: T-Lymphocytes RegulatoryMESH : HumansMESH: AdultTh1 Cellsmedicine.diseaseMESH : Giant Cell ArteritisMESH: Prospective StudiesMESH: MaleGiant cell arteritisMESH: Th1 CellsPolymyalgia RheumaticaMESH: Polymyalgia RheumaticaImmunologyTh17 CellsMESH : Polymyalgia RheumaticaMESH: Female
researchProduct

Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.

2018

International audience; Objective - To compare long-term efficacy of remission-maintenance regimens in patients with newly diagnosed or relapsing antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitides. Methods - The 28-month Maintenance of Remission using Rituximab in Systemic ANCA-associated Vasculitis trial compared rituximab with azathioprine to maintain remission in patients with newly diagnosed or relapsing granulomatosis with polyangiitis, microscopic polyangiitis or renal-limited ANCA-associated vasculitis. Thereafter, prospective patient follow-up lasted until month 60. The primary endpoint was the major-relapse rate at month 60. Relapse and serious adverse event-free …

MaleAzathioprineKaplan-Meier Estimateurologic and male genital diseasesGastroenterologySeverity of Illness Index0302 clinical medicineimmune system diseasesRecurrenceRisk FactorsAzathioprineClinical endpointImmunology and Allergy030212 general & internal medicineskin and connective tissue diseasestreatmentRemission InductionMiddle Aged3. Good healthTreatment OutcomeAntirheumatic AgentsRituximabFemalesystemic vasculitisGranulomatosis with polyangiitisMicroscopic polyangiitisVasculitisRituximabImmunosuppressive Agentsmedicine.drugSystemic vasculitisAdultmedicine.medical_specialtyImmunologyAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisGeneral Biochemistry Genetics and Molecular BiologyDrug Administration ScheduleAntibodies Antineutrophil Cytoplasmic03 medical and health sciencesRheumatologyInternal medicinemedicineHumanscardiovascular diseasesLymphocyte CountGlucocorticoidsAnti-neutrophil cytoplasmic antibodyAged030203 arthritis & rheumatology[SDV.GEN]Life Sciences [q-bio]/Geneticsgranulomatosis with polyangiitisDose-Response Relationship Drugbusiness.industrymedicine.diseaserespiratory tract diseases[ SDV.GEN ] Life Sciences [q-bio]/GeneticsbusinessAnnals of the rheumatic diseases
researchProduct

A comparison between nailfold capillaroscopy patterns in adulthood in juvenile and adult-onset systemic sclerosis: A EUSTAR exploratory study.

2015

Objective: Qualitative capillaroscopy patterns in juvenile- and adult-onset systemic sclerosis (SSc) were studied in adulthood using data from the EULAR Scleroderma Trials and Research (EUSTAR) database. Methods: Data collected between June 2004 and April 2013 were examined with focus on capillaroscopy. In this retrospective exploratory study, series of patients with juvenile-onset SSc were matched with series of adult-onset SSc having the same gender and autoantibody profile. Results: 30 of 123 patients with juvenile-onset and 2108 of 7133 with adult-onset SSc had data on capillaroscopy. Juvenile-onset SSc showed scleroderma pattern more frequently than adult-onset SSc (93.3% and 88%). The…

AdultMalemedicine.medical_specialtyPathologyAdolescentKlinikai orvostudományokBiochemistryJuvenile systemic sclerosiSclerodermaMicroscopic AngioscopySystemic sclerosiScleroderma LocalizedYoung AdultMedicineJuvenileHumansYoung adultAge of Onsetskin and connective tissue diseasesChildNailfold CapillaroscopyVideocapillaroscopyAgedRetrospective StudiesEUSTARScleroderma Systemicintegumentary systemCapillaroscopybusiness.industrySimilar distributionMicrocirculationAutoantibodyRetrospective cohort studyOrvostudományokCell BiologyMiddle Agedmedicine.diseaseDermatologyCapillariesNailfold capillaroscopyFemaleAge of onsetCardiology and Cardiovascular MedicinebusinessCapillaroscopy; EUSTAR; Juvenile systemic sclerosis; Microcirculation; Nailfold capillaroscopy; Systemic sclerosis; Videocapillaroscopy; Biochemistry; Cardiology and Cardiovascular Medicine; Cell BiologyMicrovascular research
researchProduct

Interstitial Lung Disease during ANCA-Associated Vasculitis: A Poor-Prognosis Factor

2018

IF 7.873; International audience

Anti-fibrosing agents[SDV.MHEP.RSOA] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system[SDV]Life Sciences [q-bio]ANCA-associated vasculitis (AAV)Interstitial lung disease (ILD)ComputingMilieux_MISCELLANEOUS
researchProduct